Dyne Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Dyne Therapeutics, Inc. (DYN) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-03-02
- Dyne Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- Dyne Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- Dyne Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- Dyne Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |